Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adicet Bio Inc (NQ: ACET )

14.67 +0.09 (+0.62%)
Streaming Delayed Price Updated: 12:35 PM EDT, Jun 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 134,789
Open 14.19
Bid (Size) 14.65 (2)
Ask (Size) 14.69 (1)
Prev. Close 14.58
Today's Range 14.08 - 14.71
52wk Range 6.250 - 21.17
Shares Outstanding 40,004,357
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Adicet Bio to Present at Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Vaxxinity (NASDAQ:VAXX) stock moved upwards by 10.2% to $3.56 during Monday's after-market session. The company's market cap stands at $448.5 million. 
Via Benzinga

Performance

YTD
-19.97%
-19.97%
1 Month
+24.11%
+24.11%
3 Month
-25.04%
-25.04%
6 Month
-8.71%
-8.71%
1 Year
+44.96%
+44.96%

More News

Read More
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Via Benzinga
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
70 Biggest Movers From Friday
Via Benzinga
20 Stocks Moving in Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Present at Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Participate in Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Where Adicet Bio Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
Via Benzinga
Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
From Adicet Bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 4, 2022
Via Benzinga
Adicet Bio to Participate in Guggenheim 2022 Oncology Conference
From Adicet Bio, Inc.
Via Business Wire
4 Stocks Insiders Are Buying
Via Benzinga
Adicet Bio Raises $87M Via Equity To Fund Development Of Non-Hodgkin's Lymphoma Candidate
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.